Epidermal growth factor receptor driver mutations, most notably in NSCLC, confer sensitivity to EGFR inhibitors, while EGFR overexpression typically does not.67,68 In ACC, over 75% of tumors express EGFR, but mutations in EGFR are rare.69 This evidence concerns the gene EGFR and non-small cell lung carcinoma.